dallas semaglutide gastric intestinal obstruction lawsuit law office glp-1 gastric intestinal obstruction law firm in kentucky glp-1 gastrointestinal semaglutide gastroparesis lawsuit in dallas

Select your current weight 286 pounds 130 175 220 265 310 355 395 440 Weight you could lose 57 pounds *In a 68- and 72-week clinical trial studying Wegovy (2.4 mg) and Zepbound (15 mg) in patients without diabetes and with BMI 30, or BMI 27 with a weight-related condition, the average weight loss was 15% and 20%, when paired with diet and exercise changes (compared to 2.4% and 3.1%, respectively, with diet and exercise alone)

In Study 5 (NCT#03548987), WEGOVY was escalated during a 20-week run-in period, and patients who reached a WEGOVY 2.4 mg subcutaneous weekly dosage after the run-in period were randomized to either continued treatment with WEGOVY or placebo for 48 weeks

A provider that skips titration steps or starts you at a high dose is cutting corners that could result in severe gastrointestinal side effects , persistent fatigue , or worse

Avoid taking Ozempic if you have: A history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, or diabetic retinopathy